These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19500984)

  • 1. Identification of compounds exhibiting inhibitory activity toward the Pseudomonas tolaasii toxin tolaasin I using in silico docking calculations, NMR binding assays, and in vitro hemolytic activity assays.
    Lee Y; Woo Y; Lee S; Kang K; Yong Y; Kim JK; Kim KP; Kim MH; Kim YK; Lim Y
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4321-4. PubMed ID: 19500984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico study of the ion channel formed by tolaasin I produced by Pseudomonas tolaasii.
    Jo G; Hwang D; Lee S; Woo Y; Hyun J; Yong Y; Kang K; Kim DW; Lim Y
    J Microbiol Biotechnol; 2011 Oct; 21(10):1097-100. PubMed ID: 22031037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temperature-dependent hemolytic activity of membrane pore-forming peptide toxin, tolaasin.
    Cho KH; Wang HS; Kim YK
    J Pept Sci; 2010 Feb; 16(2):85-90. PubMed ID: 19960443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A left-handed alpha-helix containing both L- and D-amino acids: the solution structure of the antimicrobial lipodepsipeptide tolaasin.
    Jourdan F; Lazzaroni S; Méndez BL; Lo Cantore P; de Julio M; Amodeo P; Iacobellis NS; Evidente A; Motta A
    Proteins; 2003 Sep; 52(4):534-43. PubMed ID: 12910453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of non-pseudomonad bacteria from fruit bodies of wild agaricales fungi that detoxify tolaasin produced by Pseudomonas tolaasii.
    Tsukamoto T; Murata H; Shirata A
    Biosci Biotechnol Biochem; 2002 Oct; 66(10):2201-8. PubMed ID: 12450133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification of a pore-forming peptide toxin, tolaasin, produced by Pseudomonas tolaasii 6264.
    Cho KH; Kim ST; Kim YK
    J Biochem Mol Biol; 2007 Jan; 40(1):113-8. PubMed ID: 17244491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two types of ion channel formation of tolaasin, a Pseudomonas peptide toxin.
    Cho KH; Kim YK
    FEMS Microbiol Lett; 2003 Apr; 221(2):221-6. PubMed ID: 12725930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An efficient in silico screening method based on the protein-compound affinity matrix and its application to the design of a focused library for cytochrome P450 (CYP) ligands.
    Fukunishi Y; Hojo S; Nakamura H
    J Chem Inf Model; 2006; 46(6):2610-22. PubMed ID: 17125201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WLIP and tolaasin I, lipodepsipeptides from Pseudomonas reactans and Pseudomonas tolaasii, permeabilise model membranes.
    Coraiola M; Lo Cantore P; Lazzaroni S; Evidente A; Iacobellis NS; Dalla Serra M
    Biochim Biophys Acta; 2006 Nov; 1758(11):1713-22. PubMed ID: 16925979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological characterization of white line-inducing principle (WLIP) produced by Pseudomonas reactans NCPPB1311.
    Lo Cantore P; Lazzaroni S; Coraiola M; Dalla Serra M; Cafarchia C; Evidente A; Lacobellis NS
    Mol Plant Microbe Interact; 2006 Oct; 19(10):1113-20. PubMed ID: 17022175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 19F NMR spectroscopy to screen chemical libraries for ligands that bind to proteins.
    Tengel T; Fex T; Emtenas H; Almqvist F; Sethson I; Kihlberg J
    Org Biomol Chem; 2004 Mar; 2(5):725-31. PubMed ID: 14985813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolaasins A--E, five new lipodepsipeptides produced by Pseudomonas tolaasii.
    Bassarello C; Lazzaroni S; Bifulco G; Lo Cantore P; Iacobellis NS; Riccio R; Gomez-Paloma L; Evidente A
    J Nat Prod; 2004 May; 67(5):811-6. PubMed ID: 15165142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adsorption of Tolaasins, the Toxins Behind Mushroom Bacterial Blotch, by Microbacterium spp. is Insufficient for Its Detoxification.
    Tomita S; Hirayasu A; Kajikawa A; Igimi S; Shinohara H; Yokota K
    Curr Microbiol; 2020 Jun; 77(6):910-917. PubMed ID: 31965226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and cytotoxicity of aurilide analogs.
    Suenaga K; Kajiwara S; Kuribayashi S; Handa T; Kigoshi H
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3902-5. PubMed ID: 18583129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Tolaasin Cytotoxicity Causing Brown Blotch Disease in Cultivated Mushrooms Using Tolaasin Inhibitory Factors.
    Yun YB; Cho KH; Kim YK
    Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a gene cluster encoding three high-molecular-weight proteins, which is required for synthesis of tolaasin by the mushroom pathogen Pseudomonas tolaasii.
    Rainey PB; Brodey CL; Johnstone K
    Mol Microbiol; 1993 May; 8(4):643-52. PubMed ID: 8332057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-based approach to in silico pharmacology: nuclear receptor profiling.
    Mestres J; Martín-Couce L; Gregori-Puigjané E; Cases M; Boyer S
    J Chem Inf Model; 2006; 46(6):2725-36. PubMed ID: 17125212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand.
    Palmioli A; Sacco E; Abraham S; Thomas CJ; Di Domizio A; De Gioia L; Gaponenko V; Vanoni M; Peri F
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4217-22. PubMed ID: 19515561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational and experimental approaches assess the interactions between bovine beta-lactoglobulin and synthetic compounds of pharmacological interest.
    Eberini I; Rocco AG; Mantegazza M; Gianazza E; Baroni A; Vilardo MC; Donghi D; Galliano M; Beringhelli T
    J Mol Graph Model; 2008 Feb; 26(6):1004-13. PubMed ID: 17905618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of ligands by a combination of computational and NMR-based screening: RNA as an example target.
    Mayer M; James TL
    Methods Enzymol; 2005; 394():571-87. PubMed ID: 15808238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.